Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
| Autor: | Harish Seethapathy, Sarah Street, Xiao Wei, Shveta S. Motwani, Kerry L. Reynolds, Toni K. Choueiri, Nifasha Rusibamayila, Ian A. Strohbehn, Meghan Lee, M.D. Michaelson, Brad McGregor, Cristina Salabao, Guru Sonpavde, Meghan E. Sise, David E. Leaf, Shruti Gupta, Sophia H. Zhao, Donald F. Chute, Xin Gao, Marina D. Kaymakcalan, Osama E. Rahma |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Renal function Renal cell carcinoma Internal medicine medicine Humans Cumulative incidence Adverse effect Carcinoma Renal Cell Immune Checkpoint Inhibitors Aged Retrospective Studies Aged 80 and over business.industry Acute kidney injury Cancer Retrospective cohort study Acute Kidney Injury Middle Aged medicine.disease Kidney Neoplasms Urinary Bladder Neoplasms Cohort Female business Glomerular Filtration Rate |
| Zdroj: | European Journal of Cancer. 157:50-58 |
| ISSN: | 0959-8049 |
| Popis: | Background In patients with genitourinary cancers, the effect of immune checkpoint inhibitors (ICIs) on kidney function is unknown. Patients and methods This is a retrospective cohort study of patients with renal cell carcinoma (RCC) and urothelial carcinoma who received ICIs at two major cancer centers between 2012 and 2018. Cumulative incidence and Fine and Gray subdistribution hazard models were performed to determine predictors of the co-primary outcomes, (1) acute kidney injury (AKI) and (2) sustained estimated glomerular filtration rate (eGFR) loss, defined as a >20% decline in eGFR sustained ≥90 days. We also determined the association between immune-related adverse events (irAE) and adverse kidney outcomes among patients surviving ≥1 year. Results 637 patients were included; 320 (50%) patients had RCC and 317 (50%) patients had urothelial carcinoma. Half of the cohort had eGFR Conclusion AKI and sustained eGFR loss are common in patients with genitourinary cancers receiving ICIs. irAEs may be a novel risk factor for kidney function decline among patients receiving ICIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect